Copyright
©The Author(s) 2021.
World J Gastroenterol. Jun 14, 2021; 27(22): 2994-3009
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.2994
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.2994
Figure 3 Distinct targeting of regulatory T cell activating and inhibitory receptor-targeted therapies in cancer and autoimmunity.
Regulatory T cell (Treg) cells are equipped with a repertoire of activating and inhibitory receptors. For successful therapy of tumors and chronic infections, blockade of activating receptors and/or stimulation of inhibitory receptors shifts the balance toward inhibition of Tregs. In contrast, to achieve Treg activation in autoimmune diseases, blockade of inhibitory receptors and/or stimulation of activating receptors may be desirable. Treg: Regulatory T cell.
- Citation: Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009
- URL: https://www.wjgnet.com/1007-9327/full/v27/i22/2994.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i22.2994